title: First-line use of enfuvirtide-containing HAART regimen with dramatic clinical and immunological improvement in three cases.
authors.forename: Anne
authors.initials: A
authors.lastname: Bourgarit
authors.forename: Caroline
authors.initials: C
authors.lastname: Lascoux
authors.forename: Pierre
authors.initials: P
authors.lastname: Palmer
authors.forename: Ewa
authors.initials: E
authors.lastname: Tuleja
authors.forename: Claire
authors.initials: C
authors.lastname: Pintado
authors.forename: Dominique
authors.initials: D
authors.lastname: Farge
authors.forename: Daniel
authors.initials: D
authors.lastname: Sereni
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000627:therapeutic use*; D023581:HIV Fusion Inhibitors / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide